Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748598 | 0.91 | KCNH2 (0.44) | KCNH2MAP4K4TBK1JAK2JAK1 | |
| SCHEMBL5748379 | 0.91 | KCNH2 (0.51) | KCNH2MAP4K4TBK1JAK2JAK1 | |
| SCHEMBL5801155 | 0.88 | KCNH2 (0.42) | KCNH2MAP4K4TBK1JAK2JAK1 | |
| SCHEMBL5775818 | 0.85 | MAP4K4 (0.45) | KCNH2MAP4K4TBK1CCNCCDK8 | |
| SCHEMBL5749568 | 0.83 | KCNH2 (0.40) | KCNH2MAP4K4TBK1JAK2JAK1 | |
| SCHEMBL5750917 | 0.81 | KCNH2 (0.41) | KCNH2MAP4K4TBK1JAK2JAK1 | |
| SCHEMBL5749905 | 0.80 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL633007 | 0.80 | KCNH2 (0.50) | KCNH2NTRK1MAP4K4TBK1PIK3CD | |
| SCHEMBL1224264 | 0.80 | MAP4K4 (0.42) | MAP4K4TBK1JAK2JAK1DDB1 | |
| SCHEMBL5747115 | 0.79 | KCNH2 (0.41) | KCNH2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419155-B1 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-20040198756-A1 | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1419155-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003010138-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198756-A1 | Medicaments | PIGO, PSAP, CD68 | KCNH2 3821/4885NTRK1 4534/4885MAP4K4 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.